Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Haufen Diagnostic Biomarkers of BK Renal Disease

This study is enrolling participants by invitation only.
Astellas Pharma US, Inc.
Information provided by (Responsible Party):
Volker Nickeleit, MD, University of North Carolina, Chapel Hill Identifier:
First received: March 25, 2010
Last updated: April 17, 2017
Last verified: April 2017
To prospectively test whether the detection of three-dimensional, cast-like polyomavirus aggregates, termed Haufen, in voided urine samples can serve as an accurate biomarker of intra-renal disease, i.e. polyoma-BK-virus nephropathy (PVN). We want to correlate the detection of 'Haufen' with histologic findings made in renal biopsies as well as signs of polyomavirus activation, i.e. viremia and viruria. The prospective study is designed to further validate our retrospective findings (manuscript in press, J Am Soc Nephrology) and more specifically to correlate 'Haufen' shedding with the histologically confirmed course of PVN.

Condition Intervention
Polyoma Virus Nephropathy
Procedure: Renal Allograft Biopsy

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Diagnostic
Official Title: Polyomavirus Aggregates, Haufen, in Voided Urine Samples as Diagnostic Biomarkers of Intra Renal BK-virus Disease: a Prospective Proof-of-concept Study

Resource links provided by NLM:

Further study details as provided by Volker Nickeleit, MD, University of North Carolina, Chapel Hill:

Primary Outcome Measures:
  • Correlate Haufen, urine and plasma data with the clinical presentation and - in selected cases - with renal biopsy findings. [ Time Frame: The biopsy will be performed when urine is determined to be Haufen negative ]

Estimated Enrollment: 10
Study Start Date: November 2008
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: July 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Renal Allograft Biopsy Procedure: Renal Allograft Biopsy
A renal allograft biopsy will be performed when the urine is determined to be Haufen negative.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 or older
  • Recipient of renal transplant
  • Positive for polyoma virus
  • Haufen cells present in urine
  • Positive for polyoma virus nephropathy

Exclusion Criteria:

  • anyone who does not meet the inclusion criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01094691

United States, North Carolina
University of North Carolina-CH Dept of Pathology
Chapel Hill, North Carolina, United States, 27599
Sponsors and Collaborators
University of North Carolina, Chapel Hill
Astellas Pharma US, Inc.
Principal Investigator: Volker Nickeleit, MD University of North Carolina, Chapel Hill
  More Information

Responsible Party: Volker Nickeleit, MD, Director of the UNC Division of Nephropathology, University of North Carolina, Chapel Hill Identifier: NCT01094691     History of Changes
Other Study ID Numbers: 08-1519
Study First Received: March 25, 2010
Last Updated: April 17, 2017 processed this record on May 25, 2017